A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.
Ben Garmezy, MD
Advertisement
Articles by Ben Garmezy, MD
A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.
The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.
Manojkumar Bupathi, MD, MS, and Ben Garmezy, MD, discuss how to optimize treatment approaches for genitourinary cancers through evaluation of real-world data, sequencing strategies, and toxicity management while working to bridge care disparities between community and academic settings.
Advertisement
Latest Updated Articles
Episode 1: NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder CancerPublished: March 4th 2025 | Updated:
- Episode 2: Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
Published: March 5th 2025 | Updated:
- Episode 3: Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma
Published: March 7th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ASH 2025: Key Anticipated Updates in the Leukemia Landscape
2
ASH 2025: Which Presentations Will Move the Multiple Myeloma Needle?
3
Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma
4
Fixed-Duration Venetoclax Combos Show Noninferior PFS to Ibrutinib in CLL
5
